Literature DB >> 15610044

Binding of antitumor antibiotic daunomycin to histones in chromatin and in solution.

Azra Rabbani1, Ron M Finn, Anita A Thambirajah, Juan Ausió.   

Abstract

Daunomycin is an anticancer drug that is well-known to interact with DNA in chromatin. Using a compositionally defined chicken erythrocyte chromatin fraction, we have obtained conclusive evidence that the drug is also able to interact with chromatin-bound linker histones without any noticeable binding to core histones. The drug can interact in an equal fashion with both histone H1 and H5 and to a greater extent with core histones H3/H4 and H2A/H2B as free proteins in solution. Thus, the binding of daunomycin to linker histones in the chromatin fiber is most likely due to the well-known higher accessibility of these histones to the surrounding environment of the fiber. Binding of daunomycin to linker histones appears to primarily involve the trypsin-resistant (winged-helix) domain of these proteins. The studies described here reveal the occurrence of a previously undisclosed mechanism for the antitumor activity of anthracycline drugs at the chromatin level.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15610044     DOI: 10.1021/bi048524p

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  10 in total

Review 1.  A revisit of the mode of interaction of small transcription inhibitors with genomic DNA.

Authors:  Dipak Dasgupta; Parijat Majumder; Amrita Banerjee
Journal:  J Biosci       Date:  2012-07       Impact factor: 1.826

2.  Daunomycin, an antitumor DNA intercalator, influences histone-DNA interactions.

Authors:  Krzysztof Wójcik; Mirosław Zarębski; Andrea Cossarizza; Jurek W Dobrucki
Journal:  Cancer Biol Ther       Date:  2013-06-14       Impact factor: 4.742

3.  Assay Development and High-Throughput Screening for Inhibitors of Kaposi's Sarcoma-Associated Herpesvirus N-Terminal Latency-Associated Nuclear Antigen Binding to Nucleosomes.

Authors:  Chantal Beauchemin; Nathan J Moerke; Patrick Faloon; Kenneth M Kaye
Journal:  J Biomol Screen       Date:  2014-02-11

4.  Anticancer drug mithramycin interacts with core histones: An additional mode of action of the DNA groove binder.

Authors:  Amrita Banerjee; Sulagna Sanyal; Kirti K Kulkarni; Kuladip Jana; Siddhartha Roy; Chandrima Das; Dipak Dasgupta
Journal:  FEBS Open Bio       Date:  2014-10-16       Impact factor: 2.693

5.  Interactions of Cisplatin and Daunorubicin at the Chromatin Level.

Authors:  Erfaneh Firouzi Niaki; Thibaut Van Acker; László Imre; Péter Nánási; Szabolcs Tarapcsák; Zsolt Bacsó; Frank Vanhaecke; Gábor Szabó
Journal:  Sci Rep       Date:  2020-01-24       Impact factor: 4.379

6.  Inhibition of N-terminal lysines acetylation and transcription factor assembly by epirubicin induced deranged cell homeostasis.

Authors:  Shahper N Khan; Mohd Danishuddin; Bhavna Varshney; Sunil K Lal; Asad U Khan
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

7.  Interaction of anthracyclines with iron responsive element mRNAs.

Authors:  Joshua C Canzoneri; Adegboyega K Oyelere
Journal:  Nucleic Acids Res       Date:  2008-10-25       Impact factor: 16.971

8.  The DNA intercalators ethidium bromide and propidium iodide also bind to core histones.

Authors:  Amrita Banerjee; Parijat Majumder; Sulagna Sanyal; Jasdeep Singh; Kuladip Jana; Chandrima Das; Dipak Dasgupta
Journal:  FEBS Open Bio       Date:  2014-02-15       Impact factor: 2.693

Review 9.  Chromatin as a target for the DNA-binding anticancer drugs.

Authors:  Parijat Majumder; Suman K Pradhan; Pukhrambam Grihanjali Devi; Sudipta Pal; Dipak Dasgupta
Journal:  Subcell Biochem       Date:  2007

10.  Doxorubicin induces large-scale and differential H2A and H2B redistribution in live cells.

Authors:  Péter Nánási; László Imre; Erfaneh Firouzi Niaki; Rosevalentine Bosire; Gábor Mocsár; Anett Türk-Mázló; Juan Ausio; Gábor Szabó
Journal:  PLoS One       Date:  2020-04-16       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.